Analysts Set Ascendis Pharma A/S (NASDAQ:ASND) Target Price at $295.39

Ascendis Pharma A/S (NASDAQ:ASND) has earned an average recommendation of “Buy” from the nineteen brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, sixteen have given a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $295.3889.

A number of analysts have recently issued reports on ASND shares. Wall Street Zen raised shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Royal Bank Of Canada boosted their price target on shares of Ascendis Pharma A/S from $250.00 to $275.00 and gave the stock an “outperform” rating in a research note on Monday, March 2nd. Barclays boosted their price target on shares of Ascendis Pharma A/S from $342.00 to $345.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Wedbush restated an “outperform” rating and issued a $273.00 price objective on shares of Ascendis Pharma A/S in a research report on Thursday, April 9th. Finally, Wells Fargo & Company reduced their price target on shares of Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND opened at $224.11 on Friday. Ascendis Pharma A/S has a 52-week low of $158.16 and a 52-week high of $250.74. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.72 and a current ratio of 1.00. The company has a market capitalization of $13.98 billion, a P/E ratio of 25.85 and a beta of 0.41. The company has a fifty day moving average of $233.52 and a 200-day moving average of $223.08.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.11. The company had revenue of $285.45 million for the quarter, compared to the consensus estimate of $362.47 million. As a group, equities research analysts predict that Ascendis Pharma A/S will post 11.73 EPS for the current fiscal year.

Insider Activity

In related news, insider Flemming Steen Jensen sold 19,460 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $238.49, for a total transaction of $4,641,015.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jean Jacques Bienaime acquired 400 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was acquired at an average price of $237.80 per share, for a total transaction of $95,120.00. Following the acquisition, the director owned 400 shares of the company’s stock, valued at approximately $95,120. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 40.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors have recently made changes to their positions in ASND. Advisory Services Network LLC purchased a new stake in shares of Ascendis Pharma A/S during the third quarter valued at approximately $26,000. Arax Advisory Partners increased its stake in shares of Ascendis Pharma A/S by 212.2% in the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 104 shares in the last quarter. Leonteq Securities AG bought a new stake in Ascendis Pharma A/S during the fourth quarter valued at about $36,000. Caitong International Asset Management Co. Ltd bought a new stake in Ascendis Pharma A/S during the fourth quarter valued at about $42,000. Finally, Jones Financial Companies Lllp grew its holdings in Ascendis Pharma A/S by 57.2% during the third quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 83 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.